# Axis A: Proteostasis & Proteinopathy
*Focus: Amyloid-beta/Tau dynamics, seeding, spread, and protein clearance mechanisms.*

## 1. æ ¸å¿ƒé‚è¼¯åœ– (Logical Framework)

```text
   â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®          â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®
   â”‚Protein Production â”‚ â”€â”€â”€ğŸ§¬â”€â”€â–¶ â”‚ Soluble Monomers  â”‚
   â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯          â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯
                                            â”‚
                                            â–¼  (Rate-Limiting Step)
   â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®          â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®
   â”‚ Clearance System  â”‚ â—€â”€â”€ğŸŒŠâ”€â”€  â”‚ Primary Nucleationâ”‚ (The "Seed" ğŸŒ±)
   â”‚  (BBB Shuttle)    â”‚          â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯
   â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯                    â”‚
             â–²                              â–¼ (Exponential Growth)
             â”‚                    â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®
             â•°â”€â”€â”€â”€â”€â”€ğŸ§¹â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ â”‚Secondary Aggregateâ”‚ (Plaques/Tangles ğŸ•¸ï¸)
                                  â•°â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯
```

## 2. æ ¸å¿ƒé‚è¼¯ (Core Logic)
è…¦é€€åŒ–ç—…ï¼ˆç‰¹åˆ¥æ˜¯ ADï¼‰çš„æ ¸å¿ƒä»åœç¹è›‹ç™½è³ªç©©æ…‹ (Proteostasis) çš„å´©æ½°ã€‚2024-2025 çš„ç ”ç©¶ç„¦é»å·²å¾å–®ç´”çš„ã€Œæ–‘å¡Šæ¸…é™¤ã€è½‰å‘ã€Œæ¸…é™¤é€Ÿç‡æ§åˆ¶ã€èˆ‡ã€Œç¨®å­æ“´æ•£å‹•åŠ›å­¸ã€ã€‚

## 3. é—œéµç ”ç©¶ç·šç´¢ (Key Clues)

### A. æ¸…é™¤æ©Ÿåˆ¶çš„ã€Œç“¶é ¸ã€çªç ´
- **ç ”ç©¶èƒŒæ™¯**ï¼šå‚³çµ±æŠ—é«”ç™‚æ³•æ•ˆæœæœ‰é™ï¼Œä¸»å› æ˜¯ BBBï¼ˆè¡€è…¦å±éšœï¼‰ç©¿é€ç‡ä½ã€‚
- **2024 çªç ´ (Nature)**ï¼šKariolis ç­‰äººåˆ©ç”¨ BBB ç©¿é€ç©¿æ¢­è›‹ç™½ (Shuttle Proteins) å¯¦ç¾äº†å¤§è…¦ç¯„åœå…§çš„æ²»ç™‚æ€§è›‹ç™½éé€ã€‚
- **ç·šç´¢ (Clue)**ï¼šæœªä¾†çš„ç ”ç©¶é‡å¿ƒå°‡åœ¨æ–¼ã€Œéé€æ•ˆç‡ã€è€Œéå–®ç´”çš„æŠ—é«”è¦ªå’ŒåŠ›ã€‚

### B. Tau è›‹ç™½èšåˆçš„å‹•åŠ›å­¸ (Kinetics)
- **2024 ç™¼ç¾ (Cell)**ï¼šMeisl ç­‰äººå»ºç«‹æ¨¡å‹æ­ç¤ºäº† Tau èšåˆåœ¨é«”å…§çš„é€Ÿæ§æ­¥é©Ÿã€‚
- **é‚è¼¯è½‰å‘**ï¼šå¾é—œæ³¨ã€Œè›‹ç™½è³ªå«é‡ã€è½‰å‘é—œæ³¨ã€Œèšåˆé€Ÿç‡ã€ã€‚
- **æœªä¾†æ–¹å‘ (Future Direction)**ï¼šå¹²é  Tau çš„åˆç´šæˆæ ¸ (Primary Nucleation) æ˜¯å¦æ¯”å¹²é å…¶æ“´æ•£æ›´æœ‰æ•ˆï¼Ÿ

## 4. å¾…è§£æ±ºçš„ç¼ºå£ (Gaps)
- å¦‚ä½•åœ¨æ´»é«”ä¸­å¯¦æ™‚å®šé‡è©•ä¼° Glymphaticï¼ˆé¡æ·‹å·´ç³»çµ±ï¼‰çš„æ¸…é™¤æ•ˆç‡ï¼Ÿ
- cccDNA å°æ–¼ç—…æ¯’èª˜å°çš„è›‹ç™½è³ªç©©æ…‹å´©æ½°æ˜¯å¦æœ‰é•·æœŸå½±éŸ¿ï¼Ÿï¼ˆè·¨å­¸ç§‘äº¤å‰é»ï¼‰

## 5. åƒè€ƒæ–‡ç» (References)
- **Meisl, G., et al. (2024).** In vivo rate-determining steps of tau aggregation in Alzheimer's disease. *Cell*.
- **Kariolis, M. S., et al. (2024).** Brain-wide therapeutic protein delivery by a blood-brain barrier-crossing shuttle. *Nature Communications*.
- **Zhen, X., et al. (2024).** GSDMD activation is the key molecular mechanism of inflammatory blood-brain barrier disruption. *Nature*.

---
[å›åˆ°ç›®éŒ„](../README.md)

